What is HC Wainwright’s Forecast for XBIO FY2026 Earnings?

Xenetic Biosciences Inc (NASDAQ:XBIO) – HC Wainwright issued their FY2026 EPS estimates for shares of Xenetic Biosciences in a research note issued to investors on Monday, November 11th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.64) per share for the year. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Xenetic Biosciences’ current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Xenetic Biosciences’ FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.75) EPS.

Xenetic Biosciences Trading Up 1.6 %

Xenetic Biosciences stock traded up $0.06 on Thursday, reaching $3.71. 517 shares of the stock were exchanged, compared to its average volume of 11,228. Xenetic Biosciences has a twelve month low of $2.78 and a twelve month high of $5.20. The firm has a fifty day moving average price of $3.89 and a two-hundred day moving average price of $3.93. The stock has a market cap of $5.72 million, a PE ratio of -1.37 and a beta of 2.25.

Xenetic Biosciences (NASDAQ:XBIO) last posted its earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.83). The business had revenue of $0.73 million for the quarter, compared to analyst estimates of $0.54 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 47.21%.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.